Magnesium Oxide in Constipation

Mori, Hideki; Tack, Jan; Suzuki, Hideji

doi:10.3390/nu13020421

Cited by 41 publications

(35 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 94 ) Hypercalcemia caused by active vitamin D3 preparations used in the treatment of osteoporosis and hypermagnesemia caused by magnesium preparations used as laxatives and antacids lead to nausea and anorexia. 95 , 96 )…”

Section: Drug-related Functional Impairment In Rehabilitation Medicinementioning

confidence: 99%

Pharmacotherapy and the Role of Pharmacists in Rehabilitation Medicine

Yoshimura¹,

Matsumoto²,

Momosaki

2022

PRM

View full text Add to dashboard Cite

Pharmacotherapy is important in older patients undergoing rehabilitation because such patients, especially those with frailty and physical disabilities, are susceptible to drug-related functional impairment. Drug-related problems include polypharmacy, potentially inappropriate medications (PIMs), and potential prescription omissions. These problems are associated with adverse drug events such as dysphagia, depression, drowsiness, falls and fractures, incontinence, decreased appetite, and Parkinson’s syndrome, leading to impaired improvement in activities of daily living (ADL), quality of life (QOL), and nutritional status. Moreover, the anticholinergic burden is associated with impaired physical and cognitive functions. Therefore, pharmacist-centered multidisciplinary pharmacotherapy should be performed to maximize rehabilitation outcomes. Pharmacotherapy includes a review of all medications, the assessment of drug-related problems, goal setting, correction of polypharmacy and PIMs, monitoring of drug prescriptions, and reassessment of drug-related problems. The goal of pharmacotherapy in rehabilitation medicine is to optimize drug prescribing and to maximize the improvement of ADL and QOL as patient outcomes. The role of pharmacists during rehabilitation is to treat patients as part of multidisciplinary teams and as key members of nutritional support teams. In this review, we aim to highlight existing evidence regarding pharmacotherapy in older adults, including drug-related functional impairment and the association between pharmacotherapy and functional, cognitive, and nutritional outcomes among patients undergoing rehabilitation. In addition, we highlight the important role of pharmacists in maximizing improvements in rehabilitation outcomes and minimizing drug-related adverse effects.

show abstract

Section: Drug-related Functional Impairment In Rehabilitation Medicinementioning

confidence: 99%

Pharmacotherapy and the Role of Pharmacists in Rehabilitation Medicine

Yoshimura¹,

Matsumoto²,

Momosaki

2022

PRM

View full text Add to dashboard Cite

show abstract

“…In Japan, magnesium oxide and anthraquinone stimulant laxatives have been widely used for treatment of chronic constipation ( 5 ). However, magnesium oxide laxatives are not recommended in patients with renal impairment because of increased risk of hypermagnesemia resulting from reduced urinary excretion of magnesium ( 6 ). Anthraquinone stimulant laxatives become less effective with long-term use and can cause melanosis coli, a dark brown-black pigmentation of the colonic mucosa ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

“…

The aim of this study was to investigate the effects of elobixibat on constipation and lipid metabolism; and determine the factors associated with the effect of elobixibat on constipation in patients with moderate to end-stage chronic kidney disease (CKD).Methods: Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3,6; stage G4,9; stage G5,9; stage G5D,18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis.Results: Elobixibat increased stool frequency from 0.5 ± 0.4 per day to 1.1 ± 0.6 per day (p < 0.001) regardless of whether patients were undergoing dialysis, on concomitant laxatives, or were administered elobixibat before or after breakfast.

…”

mentioning

confidence: 99%

“…Methods: Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3,6; stage G4,9; stage G5,9; stage G5D,18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

Objective:The aim of this study was to investigate the effects of elobixibat on constipation and lipid metabolism; and determine the factors associated with the effect of elobixibat on constipation in patients with moderate to end-stage chronic kidney disease (CKD).Methods:Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3, 6; stage G4, 9; stage G5, 9; stage G5D, 18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis.Results:Elobixibat increased stool frequency from 0.5 ± 0.4 per day to 1.1 ± 0.6 per day (p < 0.001) regardless of whether patients were undergoing dialysis, on concomitant laxatives, or were administered elobixibat before or after breakfast. Elobixibat reduced low-density lipoprotein cholesterol concentration (from 90.9 ± 37.2 mg/dL to 77.5 ± 34.8 mg/dL, p < 0.05) and increased high-density lipoprotein cholesterol concentration (from 44.9 ± 14.3 mg/dL to 57.0 ± 25.8 mg/dL, p < 0.05), but did not change triglyceride concentration. Adverse effects were observed in two patients (nausea and diarrhea). Only phosphate concentration was correlated with the change in stool frequency after initiation of elobixibat (standard coefficient = 0.321, p = 0.043).Conclusions:Elobixibat improved constipation and lipid metabolism in patients with moderate to end-stage CKD, without serious adverse events.

show abstract

“…Compared to the newer drugs to treat constipation, magnesium is safe and of low cost, but daily use, particularly in patients with renal impairment, might lead to hypermagnesemia. Therefore, monitoring the magnesium concentration should be recommended [ 19 ].…”

mentioning

confidence: 99%